Semaglutide vs Tirzepatide: 2026 Honest Comparison

Mechanism — what each drug actually does

Semaglutide and tirzepatide both act on receptors that regulate appetite, blood glucose, and gastric emptying, but they engage different combinations of those receptors. The mechanistic difference matters for both the efficacy gap seen in trials and the side effect picture.

Semaglutide — GLP-1 receptor mono-agonist

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Endogenous GLP-1 is an incretin hormone released by intestinal L-cells after a meal. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system pathways. Semaglutide is a structurally modified GLP-1 analog that resists the rapid degradation that limits the half-life of native GLP-1, giving it a once-weekly subcutaneous dosing profile under its branded forms (Ozempic for diabetes, Wegovy for chronic weight management). The once-daily oral semaglutide tablet (Rybelsus) and the 25 mg oral Wegovy formulation approved in January 2026 use absorption enhancers to overcome the peptide's poor oral bioavailability.

Tirzepatide — dual GIP and GLP-1 receptor agonist

Tirzepatide is a once-weekly synthetic peptide that engages both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is the other major incretin hormone. The clinical hypothesis behind dual agonism was that hitting both receptors simultaneously would produce greater metabolic effect than mono-agonism, and that the GIP component might modulate the GI side effect profile and lipid metabolism in ways pure GLP-1 agonism cannot. The pivotal trials supported the efficacy hypothesis. The side effect picture is more nuanced — tirzepatide is not categorically more tolerable than semaglutide, though some clinical observations suggest particular patterns differ. Tirzepatide is branded as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.

The plain-English summary: semaglutide hits one incretin receptor; tirzepatide hits two. That is the basic structural difference behind every comparison that follows.

Efficacy — what the pivotal trials actually showed

Efficacy is the part of this comparison most people skip to. The honest answer requires looking at the actual numbers, the trial populations, and the duration of treatment — not at the marketing claims around either drug.

STEP-1 (semaglutide 2.4 mg) — PMID 33567185

The STEP-1 trial enrolled 1,961 adults with BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, without type 2 diabetes. Participants received once-weekly subcutaneous semaglutide 2.4 mg or placebo over 68 weeks, alongside lifestyle intervention. The result: mean body weight reduction of 14.9 percent in the semaglutide arm versus 2.4 percent in the placebo arm. Approximately 86 percent of the semaglutide group lost 5 percent or more of body weight, 69 percent lost 10 percent or more, 50 percent lost 15 percent or more, and 32 percent lost 20 percent or more. This is the headline efficacy signal for semaglutide in chronic weight management.

SURMOUNT-1 (tirzepatide) — PMID 35658024

The SURMOUNT-1 trial enrolled 2,539 adults with BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, without type 2 diabetes. Participants received once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, over 72 weeks. The result: mean body weight reduction of approximately 22.5 percent at the 15 mg dose, 21.4 percent at 10 mg, and 16.0 percent at 5 mg, versus 2.4 percent for placebo. Approximately 91 percent of the 15 mg group lost 5 percent or more, 83 percent lost 10 percent or more, 70 percent lost 15 percent or more, and 55 percent lost 20 percent or more.

SURPASS-2 head-to-head — tirzepatide vs semaglutide in type 2 diabetes

The SURPASS-2 trial provided the closest thing to a direct head-to-head comparison in type 2 diabetes. Tirzepatide at 5, 10, and 15 mg was compared against semaglutide 1.0 mg over 40 weeks in 1,879 adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide produced greater HbA1c reduction and greater body weight reduction than semaglutide 1.0 mg at all three doses. The trial is not a perfect read-across to chronic weight management because the dosing is different — Wegovy uses 2.4 mg semaglutide rather than 1.0 mg — but it remains the most direct head-to-head data available.

The cross-trial pattern is consistent: in the populations and doses studied, tirzepatide produced larger mean body weight reductions than semaglutide. The gap is meaningful, on the order of 5 to 8 percentage points between the highest doses of each. That said, every comparison has caveats — trial populations differ, individual response varies significantly, and trial outcomes are not guaranteed real-world outcomes.

What happens when treatment stops — STEP-4

STEP-4 (PMID 33933205) followed participants who had reached the maintenance dose of semaglutide 2.4 mg and then either continued or switched to placebo. The continuation group maintained their weight loss; the discontinuation group regained a substantial portion over the following year. The signal is consistent across the GLP-1 class — these are chronic medications for a chronic condition, not a fixed-duration course. The discontinuation pattern is part of the realistic decision picture for either drug.

Side effect profiles — where they overlap and where they differ

Both drugs share the GLP-1 receptor agonist side effect signature. Both require gradual dose titration to mitigate the most common adverse events. The differences are matters of degree more than kind.

Gastrointestinal — the dominant side effect class

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the most common adverse events for both semaglutide and tirzepatide. In STEP-1, gastrointestinal events were reported by approximately 74 percent of semaglutide participants versus 48 percent of placebo. In SURMOUNT-1, gastrointestinal events were reported across the tirzepatide dose tiers at broadly comparable rates, with nausea rates trending slightly higher at the 10 mg and 15 mg tirzepatide doses than at the equivalent semaglutide dose. Most GI events are mild to moderate and concentrated in the initial titration phase. Dropout rates due to GI events were roughly 4-7 percent across both pivotal trials.

Less common but more serious adverse events

• Pancreatitis: Listed as a warning in the prescribing information for both drugs. Rare in the trials. Patients with prior pancreatitis history should discuss with their prescriber.
• Gallbladder events (cholelithiasis, cholecystitis): Both drugs increase risk, partly attributable to rapid weight loss. Risk is dose-related.
• Hypoglycemia: Predominantly a concern when GLP-1 receptor agonists are combined with insulin or sulfonylureas in diabetic patients. Less of an issue when used alone for chronic weight management.
• Thyroid C-cell tumors: Boxed warning on both drugs based on rodent studies. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Acute kidney injury: Has been reported, often in the context of dehydration secondary to vomiting or diarrhea.

Both drugs are prescription medications with a prescribing information document that runs into the tens of pages. The list above is not exhaustive. A prescriber who knows your medical history is the appropriate filter for whether either drug is a reasonable fit.

Dose titration — what the schedules actually look like

Semaglutide for chronic weight management starts at 0.25 mg once weekly for four weeks, escalating through 0.5 mg, 1.0 mg, 1.7 mg, to the maintenance dose of 2.4 mg over approximately 16-20 weeks. Tirzepatide starts at 2.5 mg once weekly for four weeks, escalating through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to the maintenance dose options of 5 mg, 10 mg, or 15 mg, with titration paced to tolerability. The titration period is when most GI side effects cluster; patients who push the schedule faster than recommended typically pay for it with worse nausea.

2026 cost — branded, telehealth, and compounded routes

Cost is where the comparison gets interesting in 2026, because the route changes the price dramatically. The same molecule can cost $129 or $1,300 per month depending on the regulatory pathway. Below are the prices as of May 2026 — these change, so verify with the provider before signing up.

Branded Wegovy and Zepbound — retail without insurance

Telehealth cash-pay programs — FDA-approved branded products

Several telehealth platforms negotiate cash-pay pricing on the FDA-approved branded products. As of May 2026, these typically run $299-$499 per month for branded Wegovy or Zepbound, depending on dose tier and program structure. The product is the same FDA-approved manufactured drug; the pricing is the differentiator.

Compounded route — 503A patient-specific (post-shortage reality)

Compounded semaglutide and compounded tirzepatide through 503A telehealth providers run substantially lower than branded options. As of May 2026, compounded semaglutide typically prices in the $129-$249 per month range; compounded tirzepatide where available typically prices in the $199-$399 per month range. The post-shortage regulatory framework has narrowed which compounding is lawful — pure copy-of-commercial compounding lost its protection when the shortage exception ended in May 2025. Compounded products operating today require a clinically significant difference (combination products, intermediate doses not commercially available, formulation changes for tolerability) or supply via a registered 503B outsourcing facility. Compounded products are never FDA-approved as finished products. For the full regulatory picture see our explainer on is compounded semaglutide legal in 2026 and the deeper-dive on compounded semaglutide cost in 2026.

Lower price isn't automatically lower quality, and higher price isn't automatically higher quality — but the trade-offs are real. Compounded preparations bypass the FDA finished-product approval process, which means batch-level oversight differs from the branded manufacturer's. The clinical efficacy literature is based on the branded products; compounded products use the same molecule but their batch-to-batch consistency depends on the specific 503A or 503B pharmacy involved.

Telehealth access in 2026 — what to expect

Both semaglutide and tirzepatide are accessible through telehealth in 2026, but the access patterns differ. Branded Wegovy and Zepbound are dispensed through platforms that work with retail and mail-order pharmacies for the FDA-approved manufactured product. Compounded versions are dispensed through telehealth platforms that work with licensed 503A pharmacies, typically with named pharmacy partners disclosed on the platform's website or on request.

Among telehealth providers we have evaluated for 503A regulatory standing and pricing transparency: SkinnyRx, SHED (ShedRx), GobyMeds, and Embody GLP1 each operate in the compounded telehealth space with named US-licensed pharmacy partners. (Eden Health affiliate program paused as of 2026-05-21; coverage retained for context but no longer an active recommendation.) Hims & Hers, Ro, Sesame Care, Henry Meds, and Mochi Health are additional providers in the broader telehealth GLP-1 market worth comparing on price, transparency, and dose-tier disclosure. None of these provide "FDA-approved compounded semaglutide" — that phrase does not exist for any compounded product — but they are operating inside the regulated compounding pathway rather than outside it. (Some links are affiliate links; affiliate status does not change editorial assessment of regulatory standing.)

For a side-by-side breakdown across providers, the best telehealth for weight loss 2026 rankings lay out methodology and per-provider verdicts. The SkinnyRx vs Hims breakdown walks through the compounded-versus-branded trade-off in detail.

Who should choose which (decision framework)

There is no single right answer to "semaglutide or tirzepatide" — there is a right answer for a specific person in a specific situation, made jointly with a licensed prescriber. Below is a framework for thinking through which side of the comparison leans your way.

When semaglutide is the better starting point

• Cost is a primary constraint and the compounded 503A route is appropriate clinically. Compounded semaglutide telehealth has the most mature infrastructure and the lowest entry pricing among GLP-1 options.
• Cardiovascular outcome data matters to the patient or prescriber — the SELECT trial demonstrated cardiovascular benefit for semaglutide in adults with overweight or obesity and established cardiovascular disease without diabetes.
• Oral administration is preferred — Rybelsus (semaglutide tablet for diabetes) and Wegovy 25 mg oral (approved Jan 2026 for weight management) are options that tirzepatide does not currently offer.
• Prior tirzepatide tolerability problems — switching down to GLP-1 mono-agonism sometimes resolves issues that GIP/GLP-1 dual agonism produced.

When tirzepatide is the better starting point

• Maximum mean weight reduction in the published evidence is the priority. SURMOUNT-1's ~22.5 percent at 15 mg over 72 weeks is the largest reduction reported in the pivotal-trial literature for either drug.
• Type 2 diabetes with weight as a secondary goal — SURPASS-2 supports stronger glycemic and weight effect at tested doses.
• Failed response on a maximal semaglutide dose — the dual agonism mechanism is a reasonable next mechanistic step rather than dose-cycling within mono-agonism.
• Insurance coverage favors Zepbound over Wegovy — formulary positioning shifts annually and is worth checking before assuming either is automatically the cheaper covered option.

When neither may be the right starting point

• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (boxed warning on both drugs).
• History of pancreatitis without prescriber-cleared mitigation.
• Active eating disorder requiring different first-line treatment.
• Pregnancy, breastfeeding, or active fertility planning (consult prescriber on timing and discontinuation).

Trade-off framing is the only honest framing here. There is no "safer than" or "better than" absolute answer that survives the clinical detail. The decision belongs with a prescriber who knows the patient.

Frequently asked questions

Bottom line and next steps

The honest verdict: in the published evidence, tirzepatide produced larger mean body weight reductions than semaglutide. The side effect profile is broadly similar. The 2026 cost picture has multiple paths — branded retail, branded telehealth cash-pay, and compounded 503A telehealth — with prices ranging from roughly $129 to $1,350 per month depending on the route. The right choice belongs with a licensed prescriber who knows your medical history; the right reading of the data is that both drugs work, tirzepatide tends to work more, and the cost and tolerability trade-offs are real and worth understanding before signing up.

Retatrutide, the triple-receptor agonist in late-stage clinical trials, is investigational and NOT FDA-approved as of May 2026 and is not a current option for either semaglutide or tirzepatide patients. For trial data and red flags on retatrutide claims see our retatrutide Phase 3 results explainer.

Practical next steps:

• Compare verified telehealth providers in our best telehealth for weight loss 2026 rankings.
• Get pricing detail in the compounded semaglutide cost 2026 breakdown.
• Confirm regulatory standing with our explainer on whether compounded semaglutide is legal in 2026.
• For a head-to-head provider comparison see SkinnyRx vs Hims.
• Browse provider reviews for operator-by-operator detail.
• Visit our FAQ for additional clinical and regulatory context.

Whichever path you take, talk to a licensed physician familiar with your medical history before starting any GLP-1 medication, branded or compounded. Trial data is one part of the decision; clinical fit for your situation is the part that matters most.

Sources & clinical references

1. [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
3. [3] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33933205
4. [4] Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
5. [5] U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information; Zepbound (tirzepatide) prescribing information. Most recent versions on file at fda.gov.
6. [6] U.S. Food & Drug Administration. FDA Drug Shortages — semaglutide entry resolved February 2025; tirzepatide resolved late 2024/early 2025.
7. [7] U.S. Food & Drug Administration. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Drug Quality and Security Act (DQSA), Public Law 113-54 (2013).

Disclaimers

FTC Affiliate Disclosure: This article contains affiliate links to telehealth providers we have evaluated. If you sign up through these links, we may receive commission at no additional cost to you. Editorial assessment is independent — efficacy and trade-off framing are based on published trial data.

Educational Disclaimer: This article is for educational purposes only and is not medical advice. Semaglutide, tirzepatide, and all GLP-1 receptor agonists are prescription medications. Trial outcomes are not consumer guarantees. Compounded products are not FDA-approved finished products. Pricing is current as of May 2026 and will change — verify with the provider before signing up. Always consult a licensed healthcare provider before starting, changing, or stopping any GLP-1 medication.